Cargando…

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Triple-negative breast cancer (TNBC) is typically treated with chemotherapeutic agents, including carboplatin (Cb), an DNA platinating agent. The O6-methylguanine-DNA-methyltransferase gene (MGMT) encodes for the protein O6-alkylguanine-DNA-alkyltransferase (MGMT protein). MGMT protein is involved i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jank, Paul, Gehlhaar, Claire, Bianca, Lederer, Caterina, Fontanella, Andreas, Schneeweiss, Karn, Thomas, Marmé, Frederik, Sinn, Hans-Peter, van Mackelenbergh, Marion, Sinn, Bruno, Zahm, Dirk-Michael, Ingold-Heppner, Barbara, Schem, Christian, Stickeler, Elmar, Fasching, Peter A., Nekljudova, Valentina, Taube, Eliane Tabea, Heppner, Frank, Müller, Volkmar, Denkert, Carsten, Loibl, Sibylle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446962/ https://www.ncbi.nlm.nih.gov/pubmed/32841306 http://dx.doi.org/10.1371/journal.pone.0238021

Ejemplares similares

Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2021)

Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
por: Laakmann, Elena, et al.
Publicado: (2019)

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
por: Stevic, Ines, et al.
Publicado: (2018)

Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial
por: Rüger, Alexandra Maria, et al.
Publicado: (2020)

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
por: Fasching, Peter A., et al.
Publicado: (2023)

Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
por: Gonçalves, Juliana Pereira Lopes, et al.
Publicado: (2023)

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
por: Jurmeister, Philipp, et al.
Publicado: (2021)

Homogeneous MGMT Immunoreactivity Correlates with an Unmethylated MGMT Promoter Status in Brain Metastases of Various Solid Tumors
por: Ingold, Barbara, et al.
Publicado: (2009)

The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy
por: Wimberger, Pauline, et al.
Publicado: (2023)

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
por: Leichsenring, Jonas, et al.
Publicado: (2022)

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
por: Witzel, Isabell, et al.
Publicado: (2019)

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020)

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
por: Issa-Nummer, Yasmin, et al.
Publicado: (2013)

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
por: Sinn, Bruno Valentin, et al.
Publicado: (2019)

Sixto Adalberto Tejeda Olivares
por: García Morales, Soledad
Publicado: (1973)

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
por: Witzel, I, et al.
Publicado: (2012)

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer
por: Stürken, Christine, et al.
Publicado: (2021)

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer
por: Stürken, Christine, et al.
Publicado: (2021)

MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma
por: Lohkamp, Laura-Nanna, et al.
Publicado: (2016)

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
por: Gerber, Bernd, et al.
Publicado: (2022)

La muerte de Sixto y otros cuentos
por: García Medina, Heriberto
Publicado: (1966)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
por: Kriegsmann, Mark, et al.
Publicado: (2014)

Electron microscopy images of monkeypox virus infection in 24-year-old man
por: Müller, Markus, et al.
Publicado: (2022)

Skin lesion specimens as first choice to detect monkeypox virus – Authors’ reply
por: Müller, Markus, et al.
Publicado: (2023)

Causes of death and comorbidities in hospitalized patients with COVID-19
por: Elezkurtaj, Sefer, et al.
Publicado: (2021)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)

Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
por: Huober, Jens, et al.
Publicado: (2023)

Why misinterpretation of electron micrographs in SARS-CoV-2-infected tissue goes viral
por: Dittmayer, Carsten, et al.
Publicado: (2020)

Using EM data to understand COVID-19 pathophysiology – Authors' reply
por: Dittmayer, Carsten, et al.
Publicado: (2021)

Deep phenotyping as a contribution to personalized depression therapy: the GEParD and DaCFail protocols
por: Lichter, Katharina, et al.
Publicado: (2023)

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study
por: Reinisch, Mattea, et al.
Publicado: (2022)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Deletion of Jun Proteins in Adult Oligodendrocytes Does Not Perturb Cell Survival, or Myelin Maintenance In Vivo
por: Schreiner, Bettina, et al.
Publicado: (2015)

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
por: Schmidt, M., et al.
Publicado: (2022)

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences
por: Priedigkeit, Nolan, et al.
Publicado: (2021)

Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade
por: Hennigs, A., et al.
Publicado: (2016)

Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry
por: Laakmann, E., et al.
Publicado: (2022)

Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Heitz, Florian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e73g0vfknh7hmsakp2gji23lkq